OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
02 avr. 2024 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
22 mars 2024 07h00 HE
|
OKYO Pharma LTD
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief
Titanium Transportation Group Reports FY 2023 Financial Results
18 mars 2024 20h17 HE
|
Titanium Transportation Group Inc
Solid Q4 2023 results supported by 32% year-over-year growth in the trucking segment, reflecting revenue contribution from recent asset-based expansion into the United States.Second consecutive...
Ero Copper Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
07 mars 2024 17h01 HE
|
Ero Copper Corp.
(all amounts in US dollars, unless otherwise noted) VANCOUVER, British Columbia, March 07, 2024 (GLOBE NEWSWIRE) -- Ero Copper Corp. (TSX: ERO, NYSE: ERO) (“Ero” or the “Company”) is pleased to...
NEURONES : Résultat net part du groupe en croissance de + 11,5% en 2023
06 mars 2024 11h40 HE
|
NEURONES
INFORMATION PRESSERubrique : Résultats annuels 2023 Nanterre, le 6 mars 2024 (après Bourse) Résultat net part du groupe en croissance de + 11,5% en 2023 Comptes au 31 décembre...
NEURONES: Net profit (group share) up 11.5% in 2023
06 mars 2024 11h40 HE
|
NEURONES
PRESS INFORMATIONHeading: 2023 annual results Nanterre, March 6, 2024 (after trading) Net profit (group share) up 11.5% in 2023 Financial statements at December 31...
银河娱乐集团 2023 年第四季度及全年业绩
28 févr. 2024 02h50 HE
|
GALAXY ENTERTAINMENT GROUP LIMITED
2023年第四季度经调整EBITDA为28亿元对比2022年第四季度为(1.63)亿元 2023年全年经调整EBITDA为100亿元,对比2022年为(6)亿元 集团全年股东应占溢利为68亿元,对比2022年为(34)亿元 宣布派发另一次特别股息每股0.30元 香港, Feb. 28, 2024 (GLOBE NEWSWIRE) --...
Galaxy Entertainment Group Reports Q4 & Annual 2023 Results
28 févr. 2024 02h50 HE
|
GALAXY ENTERTAINMENT GROUP LIMITED
Q4 2023 Group Adjusted EBITDA of $2.8 Billion,Versus $(163) Million in Q4 2022 2023 Full Year Group Adjusted EBITDA of $10.0 Billion Versus $(0.6) Billion in 2022 2023 Full Year Group NPAS of $6.8...
CNOVA NV : Activité du 4ème trimestre & résultats financiers 2023
27 févr. 2024 11h59 HE
|
Cnova N.V.
CNOVA N.V.Résultats financiers annuels 2023 et activité du 4ème trimestre 2023Point sur la situation du groupe Casino Amélioration de la performance opérationnelle avec un EBITDA en hausse de +56% en...
CNOVA NV: 2023 Fourth Quarter Activity & Full Year Financial Performance
27 févr. 2024 11h59 HE
|
Cnova N.V.
CNOVA N.V.Full Year Financial performance & Fourth Quarter 2023 activityUpdate on Casino group situation Stronger operational performance with an EBITDA improving by +56% in FY23 vs. 22...